REDEFINING CANCER TREATMENT WITH NEXT-GENERATION ANTIBODIES
Leverage our scientific expertise and proprietary BiXAb platform to develop the next stage of antibody-based therapies in cancer treatment
Introduction
Innovative Antibodies to transform cancer care
Biomunex is a Paris and Cambridge based biopharmaceutical company developing breakthrough antibody-based therapies in immuno-oncology.
With our proprietary BiXAb® platform, we design and develop bi- and multi-specific antibodies that combine speed, robustness, and superior drug-like properties.
Our disruptive MAIT Engagers program opens a new therapeutic frontier by mobilizing a unique T-cell sub-population to fight solid tumors.
Science
Science & Innovation
We are committed to transforming cancer treatment by developing next-generation immunotherapies that go beyond traditional monoclonal antibodies.
BiXAb® Platform
Biomunex’s proprietary best-in-classplatform for the development of bispecific antibodies for cancer treatment
MAIT Engagers
Biomunex’s unique approach for the redirection of MAIT cells to target anddestroy solid tumors
Products & Pipeline
Innovative programs from discovery to clinical development, in collaboration with global leaders
Our Science at a Glance
We are committed to transforming cancer treatment by developing next-generation immunotherapies that go beyond traditional monoclonal antibodies.
BiXAb® Platform
Fast, robust, versatile bi- and multi-specific antibodies
MAIT Engagers
A first-in-class approach to mobilize a unique T-cell subset
Pipeline
Innovative programs from discovery to clinical development, in collaboration with global leaders
About
Understand our technology in 3 questions to Biomunex’s management Team
Pierre-Emmanuel Gerard, Founder, President & CEO and Simon Plyte, CSO
Partnering
Trusted by Leading Partners
We collaborate with leading pharmaceutical companies and world-class research institutions to accelerate innovation and bring new therapies to patients.
Key figures
+10
Years of research in immuno-oncology
3
Licensed clinical programs
2
“Deal of The Year” awards nominations
610m
Dollars in potental milestones with Ipsen
Careers
Join Our Mission
We are building a passionate and talented team to shape the future of cancer immunotherapy.
